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Conclusions: EPIC-CP was highly endorsed from healthcare 
practitioners and prostate patients across participating cancer 
centres. The EPIC-CP tool captures prostate-specific symptom 
information that assists in enhancing clinical care and symptom 
management. Provincial roll-out of EPIC-CP as a standard of care 
for PROs in clinical practice is recommended. 
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INCREASING USE OF ACTIVE SURVEILLANCE AMONGST RADIATION 
ONCOLOGISTS IN CANADA  
Jordan Stosky, Kevin Martell, Siraj Husain, Michael Peacock 
University of Calgary, Calgary, AB 
 
Purpose: To determine the preferences of radiation oncologists 
in Canada for treatment of low-risk and intermediate-risk 
prostate cancer in an era when no “gold standard” has been 
defined. 
Methods and Materials: A 20-item email questionnaire was sent 
to all practising radiation oncologist in Canada. Responses were 
collected over a four-week interval and are reported 
anonymously as aggregate. 
Results: Thirty-three responses were collected from 10 
provinces. All but two respondents treated prostate cancer 
routinely and saw between six and 30 new patients per month. 
Seventeen out of 31 (55%) prostate cancer treating respondents 
indicated they recommended active surveillance (AS) more 
frequently now compared to five years ago, whereas eight (26%) 
have not made a change in practice. Twenty-two (68%) 
respondents cited the Klotz criteria (PSA ≤ 10ng/mL, Gleason 
score of ≤ 6 or age ≥ 70 years and PSA ≤ 15 and Gleason score of 
≤ 3 + 4) or patient preference as reasons for offering AS. Twenty-
five (81%) would first recommend AS for low-risk prostate cancer. 
Almost all respondents would take the patient off AS for disease 
progression of any type (pathologic, clinical, or biochemical) or 
if the patient decided for treatment with no progression of 
disease. Twenty-two (69%) felt radical prostatectomy (RP) and 
brachytherapy (BT) were equivalent. Two (6%) felt cure rates 
were better with RP and eight (25%) felt BT cure rates were 
better. Eighteen (56%) of respondents would only recommend BT 
to patients with intermediate-risk prostate cancer; nine (28%) 
would outline options of BT, RP and external beam radiotherapy 
(EBRT). If BT was not a treatment option, then 18 (56%) 
respondents would support RP over EBRT. 
Conclusions: This survey confirmed that AS is more strongly 
favoured across Canada by radiation oncologists who treat low 
and select intermediate-risk prostate cancer. BT and RP continue 
to be the preferred recommendations. There was a bias towards 
belief that BT cure rates are better despite the lack of 
randomized evidence. EBRT is felt by most to be less curative 
than either RP or BT. 
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Purpose: To determine the maximum tolerated dose (MTD) of 5 
fraction stereotactic radiosurgery (SRS) delivered with 
concurrent and adjuvant temozolomide (TMZ) in newly diagnosed 
glioblastoma multiforme (GBM).  
Methods and Materials: Adult patients with newly diagnosed 
GBM were treated with escalating doses of SRS in a 3+3 design on 
4 dose levels: 25 Gy, 30 Gy, 35 Gy, and 40 Gy targeting the 
cavity/residual tumour with a 5 mm CTV margin and 0 mm PTV. 
There were 2 arms per PTV size: < 60 cm3 (Arm 1) and 60-150 cm3 
(Arm 2). A dose limiting toxicity (DLT) was defined as CTCAE 
Grade 3-5 CNS toxicity within 30 days of SRS, with life-long 
assessment for late SRS-related adverse radiation effect (ARE). 
The maximum tolerated dose (MTD) was the highest dose where 
0-1 out of six had an acute or late CNS Grade 3-5 toxicity. 
Secondary endpoints included progression free survival (PFS) and 
overall survival (OS). Given the difficulty in interpreting post-SRS 
imaging, any new enhancement was scored as: 1) tumour 
progression, if ultimately determined to be recurrent tumour 
(PD); 2) transient ARE if occurred within five months and 
resolved (i.e., pseudoprogression, PP); 3) persistent ARE (i.e., 
radionecrosis, RN). All AREs were scored per CTCAE.  
Results: From 2010 to 2015, 30 total patients were enrolled. The 
median age was 66 with median KPS of 80. The median GTV was 
26.8 cc (range 3.8–81.0 cc) with a PTV of 60.2 cc (range 14.7–
137.3). Protocol defined DLTs occurred in 2 patients: one 
admitted for PD at 3 weeks (Grade 4, Arm 2, Dose 40 Gy); another 
patient died 1.5 weeks post-SRS from suspected post-operative 
complications (Grade 5, Arm 1, Dose 40 Gy). AREs occurred in 11 
patients: five cases of PP occurring at a median time of 2.8 
months from SRS (range 0.8-3.4); 6 cases of RN (Grade 1 n = 2, 
Grade 2 n = 4) at 6.9 months (range 3.2–12.6). All patients with 
PP and all but one with RN had MGMT methylated tumours. 
Extent of resection (HR 0.19) and MGMT methylation (HR 0.36) 
were associated with improved OS on multivariate analysis. RN 
was not associated with increase in dose, GTV or PTV volume. 
Ultimately, 25 (83%) of patients were treated with bevacizumab, 
started in 17% for symptomatic transient ARE, 6% for persistent 
ARE, and 60% for PD. With a median follow up of 12.9 months, 
the median OS for all patients was 15.0 months, with a median 
PFS of 6.37 months. Median OS was 20.0 months for patients with 
MGMT methylated tumours, versus 11.3 months for MGMT 
unmethylated (p = 0.046). Presence of RN was associated with 
improved median OS (33.2 versus 11.3 months; p = 0.024). 
Amongst MGMT methylated patients who developed RN, median 
OS was 33.5 versus 16.9 months for those without RN (p = 0.10).  
Conclusions: The primary endpoint of dose escalation to 40 Gy 
was achieved without severe treatment-related toxicity. 
However, a dose recommendation based on tumour size cannot 
be made. These results suggest that SRS with concurrent TMZ 
constitutes a safe and feasible treatment for GBM with OS 
comparable to conventional fractionation. 
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WHEN PLANNING HIGH-DOSE RATE PROSTATE BRACHYTHERAPY?  
Audrey Tetreault-Laflamme, Cynthia Araujo, Francois Bachand, 
Matthew Schmid, Deidre Batchelar, Juanita Crook 
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Purpose: To assess adequacy of a Foley catheter for urethral 
delineation for evaluation of urethral dose in high-dose rate 
prostate brachytherapy(HDR-PB). 
Methods and Materials: Twenty-one sets of prostate ultrasound 
images were recorded with and without a Foley catheter in 
place. The first images were obtained during HDR-PB for 
intraoperative planning with a Foley catheter in-situ. A standard 
6mm-diameter circle was used to delineate the catheter on 
transverse images, assuming that it represented the urethra. 
Dosimetric optimization parameters were Prostate V100%≥98%, 
V125%: 55-62% and D90% ≥ 100% and urethral V115% = 0 cc. After 
treatment, another set of images was recorded after removing 
the catheter and instilling aerated gel into the urethra without 
removing the brachytherapy needles or changing the patient’s 
position. The images were fused using either Vitesse3.0 or 
BrachyVision11.0. Urethral dosimetric parameters, position and 
volume of the urethra were compared. Paired Student’s t-tests 
were performed for statistical analysis. 
Results: Images were recorded on 16 intermediate to high-risk 
prostate cancer patients who received HDR-PB boost combined 
with 46 Gy/23 fractions external beam radiotherapy. Eight had 
two fractions of 10 Gy in separate implants and the remaining 
eight received 15 Gy in one fraction. Twenty-one paired sets of 
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prostate ultrasound images with either a Foley or gel were fused 
and analyzed. The catheter tends to take a path of least 
curvature and is thus located in the anterior urethra. At mid-
prostate the difference is most pronounced with the posterior 
edge of the catheter located up to 7 mm anterior to the posterior 
aspect of the gel-filled urethra. Urethra V115% was higher when 
the urethra was defined with gel. Median V115% was 0 cc (0-0.03) 
with catheter compared to 0.03 cc (0-0.53) with gel (p = 0.02) 
and translated to a median V115% of 0% (0-2.14) versus 3.23% (0-
20.95) (p = 0.003), respectively. Only one patient when analyzed 
with the gel had a V118% > 10%(16.6%) and three had a V125% > 
0 cc (p = 0.31). The urethral volume was 1.4 cc (1.04-1.85) using 
the 6mm circle and was 1.22 cc(0.7-2.53) when using aerated gel 
(p = 0.522). At the prostate base and apex the smaller diameter 
of the urethra makes visualization with gel alone difficult. 
Conclusions: Using a Foley catheter for urethral identification 
and dose prescription underestimates the dose that is actually 
received by some patients. Urethral curvature differs from the 
Foley catheter, especially at mid gland where the catheter rides 
anteriorly. A standard 6 mm circle does not represent the entire 
urethral volume. Although we have not observed unexpected 
toxicity, we will continue to monitor actual urethral dose to 
correlate with toxicity in future patients. In the meantime, use 
of a catheter is the most reliable means of visualizing the entire 
length of the prostatic and membranous urethra. Consideration 
could be given to expanding the 6 mm circle in the posterior 
direction in mid-gland. 
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Purpose: To evaluate long-term biochemical control (bRFR) and 
radiation toxicity for men with localized prostate cancer treated 
with two moderately hypofractionated IG-IMRT regimens. 
Methods and Materials: Eligible consenting men with T1c-T3a Nx 
M0 prostate cancer were enrolled in a Phase II trial and received 
IG-IMRT to a risk-adapted volume that included prostate +/- 
seminal vesicles at 3 Gy per fraction, 5 days per week in 
sequential cohorts to a total dose of either 60 Gy or 66 Gy. Late 
gastrointestinal (GI) and genitourinary (GU) toxicity were 
recorded at each follow up using the Radiation Therapy Oncology 
Group criteria and biochemical failure was scored using the PSA 
nadir+2 criteria. Outcome estimates were calculated using the 
Kaplan-Meier method and log rank test. Early stopping rules 
terminated accrual to the 66 Gy cohort due to excessive Grade 
3-4 late toxicity. 
Results: Ninety-six men received 6 0Gy and 28 received 66 Gy. 
Androgen deprivation therapy (3-36 months duration) was used 
in 10% of men in both cohorts. For each cohort, the median age 
was 71 years (60 Gy) and 70 years (66 Gy). Low or intermediate-
risk presentation was respectively 27% and 65% (60 Gy) and 25% 
and 71% (66 Gy). Median follow up was 128 months (60 Gy) and 
108 months (66 Gy). The five- and eight-year bRFR for 60 Gy and 
66 Gy were respectively 83% and 67% versus 88.5% and 73.4% (p 
= 0.224). For each cohort, five (60 Gy) and one (66 Gy) subjects 
died from disease. Overall five- and eight-year cumulative late 
Grade 1-4 GI toxicity for 60 Gy versus 66 Gy were respectively 
21.2% and 21.2% versus 44.6% and 48.9% (p = 0.004). Cumulative 
late Grade 1-4 GU toxicities were respectively 23.8% and 32.8% 
versus 40.4% and 51.4% (p = 0.048). Cumulative five- and eight-
year late Grade 3-4 GI toxicity for 60 Gy and 66 Gy were 
respectively 1.1% and 1.1% versus 11.5% and 11.5% (p = 0.01). 
Cumulative five- and eight-year late Grade 3-4 GU toxicity for 60 
Gy and 66 Gy were respectively 0 and 1.5% versus 3.7% and 3.7% 
(p = 0.41). At last follow up in the 60 Gy cohort there were no 
Grade ≥ 3 late GI toxicities and one Grade 3 late GU toxicity. In 
the 66 Gy cohort there was one Grade 4 late GI toxicity and one 
Grade 4 late GU toxicity. 
Conclusions: Moderate hypofractionation to 60 Gy was 
associated with modest late toxicity and provided excellent five-
year bRFR for our patients, although failures continued to be 
observed with subsequent follow up. Dose escalation to 66 Gy 
was associated with significantly worse late GI and GU toxicity 
without an apparent improvement in bRFR. 
 
40 
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Purpose: To determine the impact of pre-treatment interstitial 
lung disease (ILD) on radiation pneumonitis and overall survival 
(OS) in patients treated with lung SBRT. 
Methods and Materials: Patients treated with lung SBRT 
between October 2004 and July 2015 at our institution were 
included. Pre-treatment CT scans were reviewed by experienced 
thoracic radiologists and interstitial changes including ground 
glass opacities (GGO), reticulations and honeycombing were 
scored and involvement to the nearest 5% was used to calculate 
Washko and Kazerooni scores. Radiation pneumonitis (RP) was 
prospectively documented using the CTCAE V4.0 criteria. Pre-
treatment imaging characteristics, lung and heart dose 
parameters and clinical variables including smoking status and 
pulmonary function were assessed by univariate (UVA) and 
multivariate analysis (MVA). OS was assessed by log rank test and 
impact of ILD on overall survival was assessed by Cox regression. 
Results: Five hundred and forty-two patients were assessed with 
56 having evidence of interstitial changes on pre-treatment 
scans. These included 12 cases of usual interstitial pneumonia 
(UIP), 18 cases of possible UIP, nine cases of non-specific 
interstitial pneumonia and 17 cases of age-related reticulations 
thought to be unrelated to ILD. RP was significantly higher in the 
39 patients with ILD (Grade ≥ 2 20.5% versus 5.8%, p < 0.01; Grade 
≥ 3 10.3% versus 1.0%, p < 0.01). Of the three cases of Grade 5 
RP observed in our series, two had imaging features of ILD. On 
UVA, radiographic evidence of ILD, Washko score, lung 
parameters (V5/V10/V15/V20/mean lung dose) and performance 
status were significant predictors of Grade ≥ 2 RP. Age-related 
reticulations were not associated with increased toxicity. On 
MVA, ILD (OR 5.18, p < 0.01) and mean lung dose (OR 1.003, p < 
0.01) were predictors of RP. ILD did not significantly affect OS 
on UVA or MVA. Median survival was 26.5 months in the ILD cohort 
and 36.6 in the ILD negative cohort (p = 0.09). 
Conclusions: Radiographic evidence of ILD is a significant risk 
factor for RP in patients treated with lung SBRT, but did not 
impact OS. CT scans should be reviewed for evidence of ILD prior 
to SBRT and involvement of respirology for management is 
essential. If ILD patients are treated with SBRT, they should be 
monitored closely for RP. 
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Purpose: Real-time transrectal ultrasound (TRUS) image 
guidance for prostate high dose-rate brachytherapy (HDR-BT) 
